AAV-mediated gene therapy demonstrates phenotypic rescue in a mouse model of Cockayne syndrome
Journal of Clinical Investigation · 2026
DOI: 10.1172/jci196689 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Ana Rita Batista und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetic and Cellular Medicine. Hauptthemen laut MEDLINE: Dependovirus, Genetic Therapy, Cockayne Syndrome, Genetic Vectors. Die Arbeit nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Riaan Research Initiative.
Abstract (Originalsprache)
Cockayne syndrome (CS) is an autosomal recessive, progressive developmental and neurodegenerative disease. Approximately 30% of cases are caused by mutations in the ERCC8/CSA gene. Patients with CS present with cutaneous photosensitivity, growth failure, shorter life span, and a progressive degeneration of the central nervous system. Loss-of-function mutations in CSA result in deficiencies in transcription-coupled nucleotide excision repair. Currently, no therapies are available for these patients. Adeno-associated virus–mediated (AAV-mediated) gene therapy offers an opportunity to address this unmet need. We designed an AAV vector encoding human CSA under a ubiquitous promoter. We tested the therapeutic efficacy of this AAV9-CSA vector by neonatal intracerebroventricular injection in the Csa –/– Xpa –/– mouse model. Treatment with AAV9-CSA resulted in a significant increase in life span, and broad distribution of human CSA in the brain and heart, without evidence of vector-related toxicity. Despite clear therapeutic benefit, we also observed neuroradiological abnormalities, and neuropathologic alterations, including hypomyelination, astrocytosis, and microgliosis, as well as likely life-limiting transcriptomic alterations in liver at endpoint. Nonetheless, the success of these experiments paves the way for clinical translation of an AAV gene therapy for patients with CS into humans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Genetic and Cellular Medicine.
- Department of Neurology.
- MD/PhD program, Morningside Graduate School of Biomedical Sciences, T.H. Chan School of Medicine, and.
- Department of Radiology, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
Förderung
- Riaan Research Initiative
Zitieren
APA
Batista, A. R., Scholand, A. C., Callahan, W. S., Watson, M. K., Sion, C. M., Mola, T., O'Hara, K., Wentworth, S. A., Sena-Esteves, W. S., King, O. D., King, R. M., & Sena-Esteves, M. (2026). AAV-mediated gene therapy demonstrates phenotypic rescue in a mouse model of Cockayne syndrome. Journal of Clinical Investigation. https://doi.org/10.1172/jci196689
Vancouver
Batista AR, Scholand AC, Callahan WS, Watson MK, Sion CM, Mola T, et al. AAV-mediated gene therapy demonstrates phenotypic rescue in a mouse model of Cockayne syndrome. Journal of Clinical Investigation. 2026. doi:10.1172/jci196689
BibTeX
@article{Batista2026,
author = {Batista, Ana Rita and Scholand, Aine C and Callahan, William S and Watson, McKenna K and Sion, Cassandra M and Mola, Tyler and O'Hara, Kennedy and Wentworth, Simon A and Sena-Esteves, William S and King, Oliver D and King, Robert M and Sena-Esteves, Miguel},
title = {AAV-mediated gene therapy demonstrates phenotypic rescue in a mouse model of Cockayne syndrome},
journal = {Journal of Clinical Investigation},
year = {2026},
doi = {10.1172/jci196689}
}
EUVIMED